In a strategic move to strengthen its commercial leadership, Kailera Therapeutics has appointed Jamie Coleman as Chief Commercial Officer. Coleman, who most recently served as Vice President and U.S. Brand Leader for Zepbound® at Eli Lilly, will oversee the commercial strategy for Kailera's clinical-stage obesity therapeutics pipeline.
Strategic Appointment Amid Clinical Progress
The appointment comes at a crucial time as Kailera prepares to advance KAI-9531, its lead candidate, into a global Phase 3 clinical program. The drug, a GLP-1/GIP receptor dual agonist, has already demonstrated positive results in Phase 2 trials for both obesity and type 2 diabetes in China, where it is being developed as HRS9531.
Ron Renaud, President and Chief Executive Officer of Kailera, emphasized the strategic importance of the appointment: "With an exceptional track record of results-driven commercial leadership, including her recent achievements in launching a blockbuster brand in the dynamic obesity space, Jamie's expertise in building and leading high-performing teams will be instrumental in helping us achieve our goal of delivering next-generation therapies."
Proven Track Record in Healthcare Commercialization
Coleman brings nearly 25 years of experience in global healthcare brand management, including a notable 17-year tenure at Eli Lilly. Her track record includes successful commercial leadership roles across multiple therapeutic areas:
- Led the accelerated launch of Zepbound® for obesity treatment
- Drove significant revenue growth as U.S. Brand Leader for Trulicity® in type 2 diabetes
- Directed global brand strategy for Jardiance®, establishing it as a leading diabetes treatment
- Oversaw global commercial strategy for Lartruvo® in solid tumor treatment
Focus on Obesity Treatment Innovation
"Obesity is one of the most urgent health challenges of our time," Coleman stated, highlighting her commitment to the role. "I'm passionate about leveraging my experience in building brands, driving cross-functional collaboration, and delivering impactful results to ultimately improve the lives of people living with obesity."
Advancing Next-Generation Therapies
Kailera Therapeutics is developing a diverse portfolio of clinical-stage injectable and oral therapies for obesity and related conditions. The company's pipeline includes multiple mechanisms and delivery routes, positioning it to potentially address various unmet needs in the obesity treatment landscape.
The appointment of Coleman signals Kailera's commitment to building a strong commercial foundation as it transitions toward late-stage clinical development and potential market entry in the competitive obesity therapeutics sector.
